Weiss Multi-Strategy Advisers’s Arcus Biosciences RCUS Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-10,000	Closed	-$122K	–	627
2018 Q2	$122K	Buy	+10,000	New	+$157K	﹤0.01%	527

Other funds holding RCUS

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Weiss Multi-Strategy Advisers's RCUS Position: Q3 2018 in Review

Weiss Multi-Strategy Advisers sold out of Arcus Biosciences (RCUS) in Q3 2018, closing a stake of 10,000 shares — an estimated $122K sold.

Weiss Multi-Strategy Advisers first reported a position in RCUS in Q2 2018 and held it in 1 quarter. The position peaked at $122K in Q2 2018. 57 funds tracked by Wall St. Rank hold RCUS as of Q3 2018.

Weiss Multi-Strategy Advisers reported no remaining Arcus Biosciences position as of Q3 2018 after selling out during the quarter.
Weiss Multi-Strategy Advisers sold 10,000 Arcus Biosciences shares in Q3 2018, an estimated $122K.
Weiss Multi-Strategy Advisers first reported a position in Arcus Biosciences in Q2 2018 and held it in 1 quarter.
Weiss Multi-Strategy Advisers's Arcus Biosciences position peaked at $122K in Q2 2018.
57 funds tracked by Wall St. Rank held Arcus Biosciences as of Q3 2018.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q3 2018, filed 14 Nov 2018.